| SYNDAX PHARMACEU.DL-,0001 |
| USA |
| Gesundheit |
| US87164F1057 / A2AFL6 |
| 1T3 (Frankfurt) / SNDX (NASDAQ) |
| FRA:1T3, ETR:1T3, 1T3:GR, NASDAQ:SNDX |
| - |
| https://www.syndax.com/ |
|
Syndax Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for cancer treatment. The primary mission of Syndax is to enhance and extend the lives of patients by significantly im..
>Volltext.. |
| 1824.66 Mio. EUR |
| 1783.27 Mio. EUR |
| 149.53 Mio. EUR |
| -236.36 Mio. EUR |
| -247.27 Mio. EUR |
| -2.86 EUR |
| 299.25 Mio. EUR |
| 116.89 Mio. EUR |
| -279.8 Mio. EUR |
| 3.28 |
| 542.44% |
| 21.08% |
| - |
| - |
| - |
| - |
| SYNDAX |
| 04.04.26 |
|